Inhibikase Therapeutics, Inc. 8-K

What Happened
Inhibikase Therapeutics, Inc. (IKT) filed a Form 8‑K on July 23, 2026 (Item 7.01) to disclose a press release announcing that the U.S. Food and Drug Administration granted Orphan Drug Designation to IKT‑001 for the treatment of pulmonary arterial hypertension (PAH). The company furnished the press release as Exhibit 99.1 to the current report.

Key Details

• Company: Inhibikase Therapeutics, Inc. (IKT).
• Event: FDA granted Orphan Drug Designation to IKT‑001 for PAH.
• Filing date: Form 8‑K filed and press release issued on July 23, 2026.
• Document: Press release furnished as Exhibit 99.1 to the 8‑K.

Why It Matters
Orphan Drug Designation is a regulatory milestone that can make a drug eligible for FDA incentives (for example, tax credits for clinical testing and potential market exclusivity if approved), which can reduce development costs and strengthen commercial prospects. This designation is not an approval; investors should view it as a positive regulatory development that supports the program’s regulatory pathway, while continuing to watch for clinical data, additional regulatory filings, and future FDA interactions.